Inceptionr LLC Buys New Position in Merck & Co., Inc. $MRK

Inceptionr LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 4,442 shares of the company’s stock, valued at approximately $534,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Chesapeake Wealth Management boosted its holdings in Merck & Co., Inc. by 0.6% in the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock worth $1,552,000 after acquiring an additional 87 shares in the last quarter. South Plains Financial Inc. lifted its holdings in shares of Merck & Co., Inc. by 0.6% in the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after purchasing an additional 89 shares in the last quarter. Syverson Strege & Co lifted its holdings in shares of Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock worth $436,000 after purchasing an additional 90 shares in the last quarter. Nations Financial Group Inc. IA ADV grew its position in Merck & Co., Inc. by 0.4% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company’s stock valued at $2,819,000 after purchasing an additional 91 shares during the period. Finally, Westside Investment Management Inc. grew its position in Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after purchasing an additional 93 shares during the period. 76.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MRK. Guggenheim lifted their price objective on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a report on Monday, July 13th. BMO Capital Markets raised their price target on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Scotiabank boosted their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a report on Tuesday, June 30th. Bank of America raised their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Finally, Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.94.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced initial access plans for alimatravir, its investigational once-monthly oral HIV PrEP in Phase 3 development, and said it has signed voluntary licensing agreements covering 129 countries. That broad access strategy could support adoption in large international markets if the drug is approved. Article Title
• Neutral Sentiment: Merck also issued a company release on the same alimatravir access plan, reinforcing that the program is moving forward and that it is trying to expand availability in regions that account for most new HIV diagnoses globally. Article Title
• Neutral Sentiment: Traders also bought a high volume of Merck call options, which may reflect rising bullish speculation around the stock and the HIV pipeline, but it does not by itself change fundamentals. Article Title
• Negative Sentiment: Par Health launched the first generic version of Janumet XR in the U.S., which may pressure Merck’s diabetes-related sales and adds another competitive headwind for an established product. Article Title

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $131.06 on Friday. The company has a market capitalization of $323.68 billion, a P/E ratio of 36.92, a P/E/G ratio of 5.20 and a beta of 0.19. The business has a fifty day simple moving average of $121.67 and a two-hundred day simple moving average of $117.71. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $131.74.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, analysts expect that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th were issued a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is presently 95.77%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.